Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Choriocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × carotuximab × Clear all
NCT01727089 2018-08-28

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
59 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡